Strategies for AE Management with T-DXd in Breast Cancer

Opinion
Video

Heather Moore, CPP, PharmD, shares expert insights on managing T-DXd-related adverse effects, including prophylactic measures for nausea and strategies for monitoring and management of ILD.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Related Content
EC Approves Ribociclib/Aromatase Inhibitor For HR+/HER2– Early Breast Cancer

EC Approves Ribociclib/Aromatase Inhibitor For HR+/HER2– Early Breast Cancer

Tim Cortese
December 2nd 2024
Article

The European Commission has approved ribociclib plus an aromatase inhibitor for patients with early breast cancer.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Treatment with (Z)-endoxifen yielded no changes in hematological safety tests among patients enrolled on the phase 2 KARISMA-Endoxifen study.

Novel SERM Reduces Mammographic Breast Density in Premenopausal Population

Russ Conroy
November 5th 2024
Article

Treatment with (Z)-endoxifen yielded no changes in hematological safety tests among patients enrolled on the phase 2 KARISMA-Endoxifen study.

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Finding a Place for Exercise Oncology in the Treatment of Breast Cancer

Neil M. Iyengar, MD
May 20th 2024
Podcast

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Findings speak to the need of cultural, racial, and ethnic inclusion when designing breast cancer trials and developing patient-reported outcome measures.

Study Shows Post-Mastectomy Disparities in Breast Cancer Minority Groups

Russ Conroy
October 31st 2024
Article

Findings speak to the need of cultural, racial, and ethnic inclusion when designing breast cancer trials and developing patient-reported outcome measures.

Four of 13 patients with metastatic breast cancer recruited in 2022 for the phase 2 clinical study evaluating Bria-IMT remain in survival follow-up.

Bria-IMT Regimen Exceeds Survival Data of SOC in Metastatic Breast Cancer

Roman Fabbricatore
October 23rd 2024
Article

Four of 13 patients with metastatic breast cancer recruited in 2022 for the phase 2 clinical study evaluating Bria-IMT remain in survival follow-up.